"The combination therapy of the novel anti-BCL-2 drug venetoclax (formerly ABT-199/GDC-0199, AbbVie, Genentech) and rituximab shows encouraging results in the treatment of refractory chronic lymphocytic leukemia (CLL), according to early results from an ongoing clinical trial.
The complete response rate seen with venetoclax is especially notable, said lead investigator Andrew W. Roberts, MBBS, PhD, from the Royal Melbourne Hospital and Walter and Eliza Hall Institute of Medical Research, in Australia."
medscape.com/viewarticle/84...
With thanks to Brian Koffman for bringing this to my attention.
Neil
Photo: Meadow Argus butterfly - with thanks as usual to Jay for identification
Zanubrutinib PFS, ORR Is Superior to Ibrutinib for Relapsed/Refractory CLL/SLL
CLL and now very elevated Monocytes
